On Monday, Shares of Microsoft Corporation (NASDAQ:MSFT), gained 0.28% to $46.23, as Technology stocks were mostly higher in late afternoon trade Monday with shares of technology companies in the S&P 500 adding 0.7%.
On June 17, In an email to employees, Microsoft Corp. declared changes to its Senior Leadership Team to drive engineering alignment against the company’s core ambitions: reinvent productivity and business processes, build the intelligent cloud platform, and create more personal computing.
“We are aligning our engineering efforts and capabilities to deliver on our strategy and, in particular, our three core ambitions,” said Satya Nadella, CEO of Microsoft. “This change will enable us to deliver better products and services that our customers love at a more rapid pace.”
Microsoft Corporation develops, licenses, markets, and supports software, services, and devices worldwide. The company’s Devices and Consumer (D&C) Licensing segment licenses Windows operating system and related software; Microsoft Office for consumers; and Windows Phone operating system.
Shares of GoPro, Inc. (NASDAQ:GPRO), declined -5.26% to $54.92, during its last trading session.
On June 1, GoPro enabler of some of today’s most immersive and engaging content, has declared the availability of its new HERO+ LCD camera. Capturing life-like high definition 1080p60 video and 8MP photos, the HERO+ LCD features a convenient touch display for easy shot framing, settings control and access to an all-new in-camera video trimming feature. Like the entry-level HERO, the HERO+ LCD is built directly into its waterproof housing. The simplicity of this all-in-one design now combines with expanded features to make capturing life’s memorable moments easier than ever.
Rugged and waterproof to 131′ (40m), HERO+ LCD also comprises advanced features like HiLight Tagging and in-camera video trimming to make it easier to identify and share your favorite moments. HiLight Tagging lets you mark key moments while recording and during playback so you can easily find them later, and the all-new video trimming feature allows you to create short clips in-camera for easier sharing without a computer.
Built-in Wi-Fi and Bluetooth® connect the HERO+ LCD to your GoPro App-enabled smartphone or tablet for easy camera control and shot preview when your camera is mounted or out of reach. The GoPro App also allows for easy content sharing to Instagram, Facebook, Twitter and more and combines with the new in-camera video trimming feature to form a convenient content sharing solution.
GoPro, Inc. develops hardware and software solutions to alleviate consumer pain points associated with capturing, managing, sharing, and enjoying engaging content. The company offers HERO line of capture devices, such as cameras; premium accessories, counting battery BacPac, smart remote, and LCD touch BacPac accessories.
Finally, BioLineRx, Ltd. (NASDAQ:BLRX), ended its last trade with 3.86% gain, and closed at $2.15.
BioLineRx Ltd., declared that it will present positive safety results of its Phase 1/2 study for BL-7010, a novel polymer for the treatment of celiac disease, at the 16th International Celiac Disease Symposium (ICDS 2015), to take place from June 21-24 in Prague, Czech Republic. The Phase 1/2 results were formerly declared in November 2014.
Yotam Nisemblat, BioLineRx Drug Development Director, will present the data in a talk titled BL-7010, a Novel Potential Treatment of Celiac Disease - a Phase 1/2 Safety Study in Celiac Patients, on Wednesday, June 24, in the Novel Treatments session. BL-7010 was found to be safe and well tolerated in the single-dose phase, and the optimal safe dose for future development was determined in the repeated-dose phase. The Company is in the final stages of additional non-clinical studies and formulation development for BL-7010 in preparation for the forthcoming randomized, placebo-controlled efficacy study, which is predictable to commence in the fourth quarter of 2015.
BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company’s development pipeline comprises of clinical-stage therapeutic candidates, counting BL-1040, a novel polymer solution for use in the prevention of ventricular remodeling following an acute myocardial infarction; BL-8040, a novel peptide for the treatment of acute myeloid leukemia, stem cell mobilization, and other hematological indications.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
